Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan J Little

Showing results (171-180 of 200) with videos related to

Pageof 20
Sort By:
The Lancet. HIV|February 2, 2024
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept studyJoseph J Eron, Susan J Little, Gordon Crofoot, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2020
Dynamics and Dispersal of Local Human Immunodeficiency Virus Epidemics Within San Diego and Across the San Diego-Tijuana BorderBram Vrancken, Sanjay R Mehta, Santiago Ávila-Ríos, et al.
JAMA Internal Medicine|November 25, 2014
Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individualsJason F Okulicz, Tuan D Le, Brian K Agan, et al.
The Journal of Infectious Diseases|June 12, 2020
Addressing Ethical Challenges in US-Based HIV Phylogenetic ResearchLiza Dawson, Nanette Benbow, Faith E Fletcher, et al.
The Journal of Infectious Diseases|February 6, 2008
Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitroKersten K Koelsch, Lin Liu, Richard Haubrich, et al.
AIDS (London, England)|October 20, 2023
People with HIV at the end-of-life and their next-of-kin/loved ones are willing to participate in interventional HIV cure-related researchSamuel O Ndukwe, Hursch Patel, Brittany Shelton, et al.
Journal of Virus Eradication|July 13, 2023
Perceived risks and benefits of enrolling people with HIV at the end of life in cure research in Southern California, United StatesKarine Dubé, Brittany Shelton, Hursch Patel, et al.
AIDS (London, England)|September 29, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individualsBrian Moldt, Huldrych F Günthard, Kimberly A Workowski, et al.
Virology|September 25, 2012
Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairmentGeorge K Hightower, Joseph K Wong, Scott L Letendre, et al.
AIDS (London, England)|June 15, 2021
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteriaJesse Fajnzylber, Radwa Sharaf, John N Hutchinson, et al.
Pageof 20

Showing results (171-180 of 200) with videos related to

Sort By:
Pageof 20
The Lancet. HIV|February 2, 2024
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept studyJoseph J Eron, Susan J Little, Gordon Crofoot, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2020
Dynamics and Dispersal of Local Human Immunodeficiency Virus Epidemics Within San Diego and Across the San Diego-Tijuana BorderBram Vrancken, Sanjay R Mehta, Santiago Ávila-Ríos, et al.
JAMA Internal Medicine|November 25, 2014
Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individualsJason F Okulicz, Tuan D Le, Brian K Agan, et al.
The Journal of Infectious Diseases|June 12, 2020
Addressing Ethical Challenges in US-Based HIV Phylogenetic ResearchLiza Dawson, Nanette Benbow, Faith E Fletcher, et al.
The Journal of Infectious Diseases|February 6, 2008
Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitroKersten K Koelsch, Lin Liu, Richard Haubrich, et al.
AIDS (London, England)|October 20, 2023
People with HIV at the end-of-life and their next-of-kin/loved ones are willing to participate in interventional HIV cure-related researchSamuel O Ndukwe, Hursch Patel, Brittany Shelton, et al.
Journal of Virus Eradication|July 13, 2023
Perceived risks and benefits of enrolling people with HIV at the end of life in cure research in Southern California, United StatesKarine Dubé, Brittany Shelton, Hursch Patel, et al.
AIDS (London, England)|September 29, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individualsBrian Moldt, Huldrych F Günthard, Kimberly A Workowski, et al.
Virology|September 25, 2012
Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairmentGeorge K Hightower, Joseph K Wong, Scott L Letendre, et al.
AIDS (London, England)|June 15, 2021
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteriaJesse Fajnzylber, Radwa Sharaf, John N Hutchinson, et al.
Pageof 20